Loading...

Paul Hartmann

OTCPK:PLHN.F
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PLHN.F
OTCPK
€1B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania. The last earnings update was 67 days ago. More info.


Add to Portfolio Compare Print
PLHN.F Share Price and Events
7 Day Returns
0%
OTCPK:PLHN.F
0.9%
US Medical Equipment
-1.4%
US Market
1 Year Returns
-
OTCPK:PLHN.F
10.9%
US Medical Equipment
1.6%
US Market
PLHN.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Paul Hartmann (PLHN.F) 0% 0% - - - -
US Medical Equipment 0.9% 1.6% -0.9% 10.9% 55.9% 90.4%
US Market -1.4% -3.9% 0.2% 1.6% 33.2% 38.2%
1 Year Return vs Industry and Market
  • No trading data on PLHN.F.
  • No trading data on PLHN.F.
Price Volatility
PLHN.F
Industry
5yr Volatility vs Market

Value

 Is Paul Hartmann undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Paul Hartmann to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Paul Hartmann.

OTCPK:PLHN.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:PLHN.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.89
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.893 (1 + (1- 30%) (1.29%))
0.934
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.934 * 5.96%)
8.3%

Discounted Cash Flow Calculation for OTCPK:PLHN.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Paul Hartmann is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:PLHN.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.3%)
2019 70.72 Est @ -2.28% 65.30
2020 70.17 Est @ -0.77% 59.83
2021 70.36 Est @ 0.28% 55.40
2022 71.08 Est @ 1.01% 51.67
2023 72.16 Est @ 1.53% 48.44
2024 73.52 Est @ 1.89% 45.58
2025 75.10 Est @ 2.14% 42.99
2026 76.84 Est @ 2.32% 40.61
2027 78.72 Est @ 2.44% 38.42
2028 80.71 Est @ 2.53% 36.37
Present value of next 10 years cash flows €484.61
OTCPK:PLHN.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €80.71 × (1 + 2.73%) ÷ (8.3% – 2.73%)
€1,489.52
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €1,489.52 ÷ (1 + 8.3%)10
€671.30
OTCPK:PLHN.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €484.61 + €671.30
€1,155.91
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,155.91 / 3.55
€325.45
OTCPK:PLHN.F Discount to Share Price
Calculation Result
Value per share (USD) From above. $399.26
Current discount Discount to share price of $365.59
= -1 x ($365.59 - $399.26) / $399.26
8.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Paul Hartmann is available for.
Intrinsic value
8%
Share price is $365.59 vs Future cash flow value of $399.26
Current Discount Checks
For Paul Hartmann to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Paul Hartmann's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Paul Hartmann's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Paul Hartmann's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Paul Hartmann's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:PLHN.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €22.25
DB:PHH2 Share Price ** DB (2019-03-21) in EUR €298
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 39.05x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 17.44x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Paul Hartmann.

OTCPK:PLHN.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:PHH2 Share Price ÷ EPS (both in EUR)

= 298 ÷ 22.25

13.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Paul Hartmann is good value based on earnings compared to the US Medical Equipment industry average.
  • Paul Hartmann is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Paul Hartmann's expected growth come at a high price?
Raw Data
OTCPK:PLHN.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 13.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
6.2%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.12x
United States of America Market PEG Ratio Median Figure of 2,121 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Paul Hartmann, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Paul Hartmann's assets?
Raw Data
OTCPK:PLHN.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €248.81
DB:PHH2 Share Price * DB (2019-03-21) in EUR €298
United States of America Medical Equipment Industry PB Ratio Median Figure of 182 Publicly-Listed Medical Equipment Companies 4.42x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
OTCPK:PLHN.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:PHH2 Share Price ÷ Book Value per Share (both in EUR)

= 298 ÷ 248.81

1.2x

* Primary Listing of Paul Hartmann.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Paul Hartmann is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Paul Hartmann's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Paul Hartmann has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Paul Hartmann expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Paul Hartmann, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Paul Hartmann expected to grow at an attractive rate?
  • Paul Hartmann's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Paul Hartmann's earnings growth is positive but not above the United States of America market average.
  • Unable to compare Paul Hartmann's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:PLHN.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:PLHN.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 6.2%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:PLHN.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:PLHN.F Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 2,125 147 79
2018-09-30 2,109 159 82
2018-06-30 2,093 170 84
2018-03-31 2,078 185 86
2017-12-31 2,063 201 88
2017-09-30 2,043 192 87
2017-06-30 2,024 183 85
2017-03-31 2,007 167 85
2016-12-31 1,991 151 85
2016-09-30 1,978 136 84
2016-06-30 1,964 122 84
2016-03-31 1,955 129 81

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Paul Hartmann's earnings are expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Paul Hartmann is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:PLHN.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Paul Hartmann Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:PLHN.F Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 22.25
2018-09-30 23.01
2018-06-30 23.74
2018-03-31 24.28
2017-12-31 24.86
2017-09-30 24.43
2017-06-30 24.00
2017-03-31 23.95
2016-12-31 23.91
2016-09-30 23.76
2016-06-30 23.61
2016-03-31 22.91

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Paul Hartmann will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Paul Hartmann's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Paul Hartmann has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Paul Hartmann performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Paul Hartmann's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Paul Hartmann's year on year earnings growth rate has been positive over the past 5 years.
  • Paul Hartmann's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Paul Hartmann's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.
Earnings and Revenue History
Paul Hartmann's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Paul Hartmann Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:PLHN.F Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2,124.87 79.02 680.42
2018-09-30 2,108.98 81.74 672.18
2018-06-30 2,093.09 84.32 664.04
2018-03-31 2,078.07 86.23 658.45
2017-12-31 2,063.05 88.30 652.76
2017-09-30 2,043.40 86.77 649.43
2017-06-30 2,023.76 85.24 646.09
2017-03-31 2,007.36 85.08 638.65
2016-12-31 1,990.96 84.92 631.21
2016-09-30 1,977.72 84.39 616.50
2016-06-30 1,964.48 83.87 601.79
2016-03-31 1,955.04 81.37 597.92
2015-12-31 1,945.61 78.87 594.06
2015-09-30 1,928.61 76.69 589.78
2015-06-30 1,911.61 74.52 585.50
2015-03-31 1,888.80 74.03 579.41
2014-12-31 1,865.99 73.55 573.32
2014-09-30 1,841.86 69.47 561.74
2014-06-30 1,817.72 65.39 550.16
2014-03-31 1,807.41 61.40 548.45
2013-12-31 1,797.11 57.41 546.75
2013-09-30 1,786.40 53.24 541.44
2013-06-30 1,775.69 49.07 536.14
2013-03-31 1,768.42 50.10 530.71
2012-12-31 1,761.15 51.13 525.28
2012-09-30 1,746.72 57.44 511.46
2012-06-30 1,732.30 64.20 498.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Paul Hartmann has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Paul Hartmann used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • Paul Hartmann's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Paul Hartmann's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Paul Hartmann has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Paul Hartmann's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Paul Hartmann's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Paul Hartmann is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Paul Hartmann's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Paul Hartmann's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 62.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Paul Hartmann Company Filings, last reported 4 months ago.

OTCPK:PLHN.F Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 923.15 13.63 107.20
2018-09-30 923.15 13.63 107.20
2018-06-30 878.79 28.37 62.10
2018-03-31 878.79 28.37 62.10
2017-12-31 854.99 38.26 73.69
2017-09-30 854.99 38.26 73.69
2017-06-30 823.04 125.86 76.04
2017-03-31 823.04 125.86 76.04
2016-12-31 816.21 22.08 109.86
2016-09-30 816.21 22.08 109.86
2016-06-30 761.82 98.72 98.57
2016-03-31 761.82 98.72 98.57
2015-12-31 759.10 69.56 90.47
2015-09-30 759.10 69.56 90.47
2015-06-30 722.11 95.64 75.46
2015-03-31 722.11 95.64 75.46
2014-12-31 690.37 104.91 89.08
2014-09-30 690.37 104.91 89.08
2014-06-30 659.74 145.50 56.62
2014-03-31 659.74 145.50 56.62
2013-12-31 647.04 138.36 56.84
2013-09-30 647.04 138.36 56.84
2013-06-30 623.73 190.63 51.17
2013-03-31 623.73 190.63 51.17
2012-12-31 613.67 146.86 48.16
2012-09-30 638.35 146.86 48.16
2012-06-30 624.04 192.46 32.21
  • Paul Hartmann's level of debt (1.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (21.4% vs 1.5% today).
  • Debt is well covered by operating cash flow (1082.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 261.7x coverage).
X
Financial health checks
We assess Paul Hartmann's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Paul Hartmann has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Paul Hartmann's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.35%
Current annual income from Paul Hartmann dividends.
If you bought $2,000 of Paul Hartmann shares you are expected to receive $47 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Paul Hartmann's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.47%).
  • Paul Hartmann's dividend is below the markets top 25% of dividend payers in United States of America (3.75%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:PLHN.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2007 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:PLHN.F Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-20 7.000 2.206
2018-03-13 7.000 2.087
2017-03-28 7.000 1.671
2016-03-23 6.700 1.635
2015-03-26 6.500 1.724
2014-03-28 5.700 1.848
2013-03-27 5.600 2.260
2012-03-28 5.500 2.591
2012-03-27 5.500 2.750
2011-02-24 5.400 2.655
2010-03-01 4.900 2.118

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Paul Hartmann has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Paul Hartmann only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Paul Hartmann's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.2x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Paul Hartmann's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Paul Hartmann afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Paul Hartmann has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Paul Hartmann's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Britta Fuenfstueck
TENURE AS CEO 0.3 years
CEO Bio

Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board since January 1, 2019. Ms. Fuenfstueck served as Chairman of the Management Board at Paul Hartmann AG since January 1, 2019 until March 2019. Ms. Fuenfstueck has been a Member of Management Board at Paul Hartmann AG since November 1, 2018. She served as member of the Executive Committee at Clariant AG from 01 April 2016 till 2018. She served as the Chief Executive Officer of the Clinical Products Division at Siemens Healthcare since 2013. From 2000 to 2009, she held various marketing and sales positions, including, Vice President as well as director roles in strategy, planning and mergers & acquisitions in the healthcare division of Siemens AG in both Germany and the United States. as well as Director, Product Portfolio and Planning, Marketing and Sales, for Siemens' Magnetic Resonance Business Unit. In 2009, she became Chief Executive Officer of the Molecular Imaging Business Unit at Siemens in Chicago, USA. In 2013 she was appointed Chief Executive Officer of the Clinical Products division at Siemens in Erlangen (Germany). She began her career in 1998 as a consultant at Boston Consulting Group. Ms. Fuenfstueck, following an education in economics, studied engineering physics at the Johannes-Kepler-University of Linz (Austria), There she completed her MSc studies in 1998.

CEO Compensation
  • Insufficient data for Britta to compare compensation growth.
  • Insufficient data for Britta to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Paul Hartmann management team in years:

8.3
Average Tenure
  • The average tenure for the Paul Hartmann management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Britta Fuenfstueck

TITLE
CEO & Member of Management Board
TENURE
0.3 yrs

Stephan Schulz

TITLE
CFO, Labor Director & Member of the Management Board
AGE
53
TENURE
10 yrs

Michel Kuehn

TITLE
Chief Commercial Officer of Hygiene & Member of Management Board
AGE
64
TENURE
10.6 yrs

Raymund Heinen

TITLE
Chief Process Officer & Member of the Management Board
TENURE
3.6 yrs

Michael Banz

TITLE
Vice President of Corporate Legal

Gabriele Müller

TITLE
Vice President of Human Resources Management
TENURE
8.3 yrs

Ralf Fenske

TITLE
Senior Vice President of Corporate Accounting

Peter Halbauer

TITLE
Head of Group Purchasing Management
TENURE
11.3 yrs

Michael Brauner

TITLE
Executive Managing Director of SANIMED Group Germany
TENURE
5.7 yrs

Christian Sievert

TITLE
Senior Vice President Business Unit Risk Prevention
Board of Directors Tenure

Average tenure of the Paul Hartmann board of directors in years:

11.1
Average Tenure
  • The average tenure for the Paul Hartmann board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Fritz-Jürgen Heckmann

TITLE
Chairman of Supervisory Board
COMPENSATION
€70K
TENURE
13.8 yrs

Ralf Willeck

TITLE
Deputy Chairman of the Supervisory Board

Wolfgang Röhrl

TITLE
Vice President Operations Management Medical Production & Member of Supervisory Board
TENURE
1.3 yrs

Eduard Schleicher

TITLE
Member of Supervisory Board
COMPENSATION
€54K
TENURE
11.1 yrs

Werner Casper

TITLE
Member of Supervisory Board
COMPENSATION
€23K

Rinaldo Riguzzi

TITLE
Member of Supervisory Board
AGE
72
TENURE
5.8 yrs

Christine Geppert

TITLE
Member of Supervisory Board
COMPENSATION
€23K

Gerhard Hirth

TITLE
Member of Supervisory Board
COMPENSATION
€23K
TENURE
11.1 yrs

Joachim Schielke

TITLE
Member of Supervisory Board
COMPENSATION
€23K
AGE
69
TENURE
11.1 yrs

Yvonne Brix

TITLE
Member of Supervisory Board
TENURE
6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Paul Hartmann's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Paul Hartmann has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania. The company offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. It also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products. The company offers its products and services to nursing and healthcare professionals, home residents, and patients. Paul Hartmann AG was founded in 1818 and is based in Heidenheim, Germany.

Details
Name: Paul Hartmann AG
PLHN.F
Exchange: OTCPK
Founded: 1818
€1,186,302,529
3,551,742
Website: http://hartmann.info
Address: Paul Hartmann AG
Paul-Hartmann-Strasse 12,
Heidenheim,
Baden-Württemberg, 89522,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB PHH2 Common Shares Deutsche Boerse AG DE EUR 02. Jan 1992
OTCPK PLHN.F Common Shares Pink Sheets LLC US USD 02. Jan 1992
Number of employees
Current staff
Staff numbers
11,027
Paul Hartmann employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 00:06
End of day share price update: 2019/03/21 00:00
Last earnings filing: 2019/03/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.